Unlike equity, royalties are a passive claim on future revenue, not profit. This top-line structure insulates the holder from operational costs, financing decisions, and accounting manipulations, making it a robust model for long-lived, capital-intensive assets like mines.

A diversified alternatives manager gains a significant advantage by seeing pricing across public equity, private equity, debt, and royalties simultaneously. This cross-asset visibility allows them to identify the best risk-adjusted return for any given opportunity, choosing to structure a royalty instead of buying equity, for example.

Altius thrives by providing capital to mining projects during industry downturns when financing is expensive or unavailable. They then benefit as the cycle turns, projects get developed with others' capital, and commodity prices rise, amplifying their royalty returns.

Since one cannot own sun or wind, Altius created novel intellectual property to structure royalty-like contractual interests in renewable projects. They provide early-stage capital to developers in exchange for a long-term revenue share from future power generation, effectively creating a new asset class.

Contrary to the focus on large upfront payments, a smarter partnership strategy is to negotiate for a larger share of downstream success through royalties and milestones. This can yield far greater long-term returns if the product succeeds.

The royalty model provides immense embedded optionality. Once the royalty is established, the holder benefits from any upside—like project expansions or new efficiencies—without having to fund the associated capital expenditures. The mine operator bears all future costs and risks for this growth.

Companies like Natural Resource Partners (NRP) own mineral rights and collect royalties per ton mined, avoiding the high operating expenses and capital expenditures of producers. This model, with 90% free cash flow margins and long-term leases, creates a durable, asymmetric bet on a commodity.

Instead of solely relying on replicating internal R&D success, a proven biotech can create value by acquiring passive assets. This involves buying royalty streams on promising external products, leveraging the company's evaluation and deal-making expertise in a new way.

Alloy Therapeutics does not compete on price with international service providers. Instead, it positions itself as a high-quality, domestic partner, structuring deals with milestones and royalties. This premium model attracts partners who prioritize the quality and functionality of the resulting drug asset over securing the lowest-cost service.